← All trials
NCT06896136
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 11, 2025
- Primary completion
- May 22, 2025
- Completion date
- May 22, 2025
- First posted
- Mar 26, 2025
- Last posted
- Jul 22, 2025
- Enrollment
- 36
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MassachusettsLead sponsor
- PharmaronCollaborator
- University of MassachusettsSponsor investigator
- University of MarylandCollaborator
- Bill and Melinda Gates FoundationCollaborator
- University of MassachusettsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.